Huadong Medicine Co., Ltd.
The Half Year Report 2021
August 2021
Section I. Important Declaration, Contents and Definitions
The Board of Directors, Board of Supervisors, directors, supervisors and
senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as
the “Company”) hereby guarantee that the information presented in this half
year report is authentic, accurate and complete and free of any false records,
misleading statements or material omissions, and shall undertake individual and
joint legal liabilities.
Lv Liang, the Company’s legal representative and the officer in charge of
accounting, and Qiu Renbo, head of accounting department (accounting
supervisor) hereby declare and guarantee that the financial statements in this
half year report are authentic, accurate and complete.
All directors have attended the Board of Directors meeting to review this
half year report.
The future plans, development strategies and other forward-looking
statements in this half year report shall not be considered as substantial
commitment of the Company to investor. Investors and related parties should
maintain sufficient risk awareness, and should understand the difference
between plans, forecasts and promises. Investors are kindly reminded to pay
attention to possible investment risks.
The Company faced various risks in its operations, involving industry
policies, markets, R&D of new drugs, product price reduction, etc. For details,
refer to “X. Risks and Countermeasures” in “Section III. Discussion and
Analysis of the Management”. We thank all investors for paying attention to the
Company’s operations, and we hope that you can be aware of investment risks.
The company does not plan to distribute cash dividends, no bonus share
will be issued; and no capital reserve will be converted to increase the share
capital.
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if
listed companies have both Chinese or other language version of public notice,
they should ensure the content of both versions are the same. In the case of
discrepancy, the original version in Chinese shall prevail.
Contents
Section I. Important Declaration, Contents and Definitions......2
Section II. Company Profile and Key Financial Indicators ......8
Section III. Discussion andAnalysis of the Management......11
Section IV. Corporate Governance ......45
Section V. Environmental and Social Responsibility ......46
Section VI. Important Matters......59
Section VII. Share Change and Shareholders ......84
Section VIII. Preferred Shares ......89
Section IX. Information about Bonds ......90
Section X. Financial Report ......91
DocumentsAvailable for Reference
I. Financial Statements carrying the signatures and stamps of the Company
Principal, the Chief Financial Officer and the person in charge of accounting firm;
II. Original copies of all documents and the announcements thereof disclosed in
the reporting period on the designated newspaper.
Definitions
Term refers to Definition
CSRC refers to China Securities Regulatory Commission
SSE refers to Shenzhen Stock Exchange
Huadong Medicine/the Company/our Company refers to Huadong Medicine Co., Ltd.
CGE refers to China Grand Enterprises, Inc.
Huadong Medicine Group refers to Hangzhou Huadong Medicine Group Co., Ltd.
Zhongmei Huadong refers to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Jiangdong Company refers to Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd.
Jiuyang Bio refers to Jiangsu Jiuyang Biopharm Co., Ltd.
Xi’an Bohua refers to Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd.
Jiuyuan Gene refers to Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Doer Biologics refers to Zhejiang Doer Biologics Corporation
Huadong Ningbo Company refers to Huadong Ningbo Medicine Co., Ltd.
Chongqing Peg-Bio refers to Chongqing Peg-Bio Biopharm Co., Ltd.
Qyuns Therapeutics refers to Qyuns Therapeutics Co., Ltd.
Nuoling Biomedical refers to Nuoling Biomedical Technology (Beijing) Co., Ltd.
Yuanda Investment Management refers to Shanghai Yuanda Investment Management Co., Ltd.
Fuguang Chengdu refers to Fuguang Chengdu Equity Investment Management Co., Ltd.
Hangzhou High-Tech refers to Hangzhou High-Tech Venture Capital Management Co., Ltd.
Yuanda Huachuang refers to Beijing Yuanda Huachuang Investment Co., Ltd.
Hangzhou Heda
查看PDF原文
